Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This study reports that cutaneous manifestations such as herpes zoster, purpura, and livedo reticularis in COVID-19 patients can potentially indicate disease severity, aiding in the prediction of the illness's progression and guiding dermatological management during the pandemic.

This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.

This review examined dermatologic symptoms associated with COVID-19 in 2,560 patients, with chilblains/pernio-like lesions being the most common, suggesting these symptoms may aid in early identification of cases.